BioSpace News Archive

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that management will present at the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced financial results for the fourth quarter and full year ended December 31, 2020.

Kadmon Holdings, Inc. provided a business update and reported financial and operational results for the fourth quarter and full year ended December 31, 2020.

CooperCompanies announced financial results for its fiscal first quarter ended January 31, 2021.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today provided a clinical programs update and reported financial results for the year ended December 31, 2020.

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and year ended December 31, 2020 on March 10, 2021 after the market close.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that Paul R.

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring systems for people with diabetes, reported financial results for the quarter and full year ended December 31, 2020.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in three upcoming investor conferences.

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the commercial launch of a generic version of ORTHO-CEPT® (desogestrel and ethinyl estradiol 0.15 mg / 0.03 mg) tablets to customers in the US.